Ophthalmology

Current approaches to vision screening in the US may not sufficiently cater to children of all sociodemographic backgrounds.

A limited number of eyes with advanced pediatric vitreoretinal diseases exhibited decreased vascular activity after intra-anterior chamber injections of ranibizumab.

Pivotal clinical trials associated with FDA ophthalmic drug approval were found to underreport and conflate sex and gender in analysis.

A new study reports previously unknown inherited genetic variants that contribute to glaucoma risk among more than 11,000 people of African ancestry.

Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.

Exposure to higher levels of outdoor artificial light at night exhibited an increased risk of incident wet age-related macular degeneration.

The FDA grants the company agreement under a Special Protocol Assessment to evaluate TRS01 ophthalmic solution for the treatment of non-infectious uveitis, including uveitic glaucoma.

Autonomous AI increases diabetic eye exam completion rates in a diverse population of youth with diabetes.

A local corticosteroid burst followed by 0.18 mg FAi may be a useful adjuvant for the treatment of noninfectious uveitis, but not sufficient as solo therapy.

The novel topical dry eye disease candidate achieved a statistically significant ≥10-mm increase in unanesthetized Schirmer’s score at Day 14.

Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.

Patients with lung cancer treated with EGFR inhibitors may experience a greater risk for keratitis, particularly with afatinib treatment.

A meta-analysis of RCTs revealed significant advantages with faricimab treatment in improving CST and reducing injection frequency among eyes with AMD or DME.

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

Results of the 76-week trial suggest that a treat-and-extend aflibercept regimen yields similar functional and anatomic outcomes as fixed dosing every 8 weeks among patients with nAMD.

Eyes with DED showed a correlation between the severity of ocular symptoms, obtained using dry eye and pain questionnaires, and all aspects of sleep quality.

A new cohort study in China reports suggests the structure of green space decreased the relative risk of myopia among school-aged children.

A retrospective cohort study showed patients with Alzheimer disease treated with AChEIs had a slightly lower risk of incident AMD compared with untreated patients.

A case-control analysis shows the majority of autoimmune diseases demonstrate no effect on the development of new-onset age-related macular degeneration.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our December 2023 month-in-review features a recap of This Year in Medicine, the latest updates to the ophthalmic pipeline, and the newest episode of our KOL-led podcast series.

Over 8 years of follow-up, patients with high myopia and a rapid progression trajectory had a nearly 7 times higher risk of developing pathological macular degeneration.

Among more than 3 million adults, a team of investigators observed an increased risk of both falls and fractures among people with cataract, age-related macular degeneration, and glaucoma.

A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.

Firework-related eye injuries were more likely in areas where fireworks were legal, compared to banned areas.

Reports of eye infection and enucleation related to OTC eye drops concerned the eye care community in 2023 and drove increased vigilance towards ensuring safer ophthalmic products.

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.

Cross-sectional data show an increasing incidence of syphilitic uveitis–related hospitalizations in the US between 2010 and 2019.

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Increases in the working-age population during the 30-year period may have contributed to the global burden of visual impairment

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.